文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

氨磺必利的新型不良事件:美国食品药品监督管理局不良事件报告系统(FAERS)数据库中的不成比例性分析。

Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.

作者信息

Subeesh Viswam, Maheswari Eswaran, Singh Hemendra, Beulah Thomas Elsa, Swaroop Ann Mary

机构信息

Department of Pharmacy Practice, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bengaluru, India.

Department of Psychiatry, Ramaiah Medical College, Bengaluru, India.

出版信息

Curr Drug Saf. 2019;14(1):21-26. doi: 10.2174/1574886313666181026100000.


DOI:10.2174/1574886313666181026100000
PMID:30362421
Abstract

BACKGROUND: The signal is defined as "reported information on a possible causal relationship between an adverse event and a drug, of which the relationship is unknown or incompletely documented previously". OBJECTIVE: To detect novel adverse events of iloperidone by disproportionality analysis in FDA database of Adverse Event Reporting System (FAERS) using Data Mining Algorithms (DMAs). METHODOLOGY: The US FAERS database consists of 1028 iloperidone associated Drug Event Combinations (DECs) which were reported from 2010 Q1 to 2016 Q3. We consider DECs for disproportionality analysis only if a minimum of ten reports are present in database for the given adverse event and which were not detected earlier (in clinical trials). Two data mining algorithms, namely, Reporting Odds Ratio (ROR) and Information Component (IC) were applied retrospectively in the aforementioned time period. A value of ROR-1.96SE>1 and IC- 2SD>0 were considered as the threshold for positive signal. RESULTS: The mean age of the patients of iloperidone associated events was found to be 44years [95% CI: 36-51], nevertheless age was not mentioned in twenty-one reports. The data mining algorithms exhibited positive signal for akathisia (ROR-1.96SE=43.15, IC-2SD=2.99), dyskinesia (21.24, 3.06), peripheral oedema (6.67,1.08), priapism (425.7,9.09) and sexual dysfunction (26.6-1.5) upon analysis as those were well above the pre-set threshold. CONCLUSION: Iloperidone associated five potential signals were generated by data mining in the FDA AERS database. The result requires an integration of further clinical surveillance for the quantification and validation of possible risks for the adverse events reported of iloperidone.

摘要

背景:信号被定义为“关于不良事件与药物之间可能的因果关系的报告信息,该关系以前未知或记录不完整”。 目的:使用数据挖掘算法(DMA),通过对美国食品药品监督管理局不良事件报告系统(FAERS)数据库进行比例失衡分析,检测伊潘立酮的新不良事件。 方法:美国FAERS数据库包含2010年第一季度至2016年第三季度报告的1028个与伊潘立酮相关的药物事件组合(DEC)。对于给定的不良事件,只有在数据库中至少有十份报告且在早期(临床试验中)未被检测到的情况下,我们才考虑对DEC进行比例失衡分析。在上述时间段内,回顾性应用了两种数据挖掘算法,即报告比值比(ROR)和信息成分(IC)。ROR-1.96SE>1和IC-2SD>0的值被视为阳性信号的阈值。 结果:发现与伊潘立酮相关事件患者的平均年龄为44岁[95%置信区间:36-51],不过有21份报告未提及年龄。经分析,数据挖掘算法对静坐不能(ROR-1.96SE=43.15,IC-2SD=2.99)、运动障碍(21.24,3.06)、外周水肿(6.67,1.08)、阴茎异常勃起(425.7,9.09)和性功能障碍(26.6-1.5)显示出阳性信号,因为这些均远高于预设阈值。 结论:通过对FDA AERS数据库进行数据挖掘,生成了与伊潘立酮相关的五个潜在信号。该结果需要进一步进行临床监测,以对伊潘立酮报告的不良事件的可能风险进行量化和验证。

相似文献

[1]
Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.

Curr Drug Saf. 2019

[2]
Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.

Pharmacotherapy. 2018-7-13

[3]
Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database.

Arab J Gastroenterol. 2023-2

[4]
Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database.

Asian J Psychiatr. 2017-9-14

[5]
Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.

Cephalalgia. 2013-8-6

[6]
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.

Expert Opin Drug Saf. 2020-7-31

[7]
Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.

Pharmacoepidemiol Drug Saf. 2018-12

[8]
Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.

Int J Clin Pharm. 2022-12

[9]
Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.

Expert Opin Drug Saf. 2023

[10]
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.

BMC Pharmacol Toxicol. 2024-9-27

引用本文的文献

[1]
Safety evaluation of tucatinib: Adverse event signal mining and analysis based on the FAERS database.

Medicine (Baltimore). 2025-8-8

[2]
Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database.

Front Oncol. 2025-7-28

[3]
Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.

Breast Cancer Res. 2025-4-9

[4]
Signal detection and analysis of adverse events associated with Genvoya based the FAERS database.

Front Pharmacol. 2024-12-4

[5]
The atypical antipsychotics and sexual dysfunction: a pharmacovigilance-pharmacodynamic study.

Front Pharmacol. 2024-7-9

[6]
Drug-associated kidney injury in children: a disproportionality analysis of the FDA Adverse Event Reporting System.

Eur J Pediatr. 2023-10

[7]
Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database.

Sci Rep. 2023-3-18

[8]
Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.

Int J Clin Pharm. 2022-12

[9]
Existence of Notoriety Bias in FDA Adverse Event Reporting System Database and Its Impact on Signal Strength.

Hosp Pharm. 2021-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索